Literature DB >> 33498866

Notch Signaling Pathway in Pancreatobiliary Tumors.

Francesca Borlak1, Anja Reutzel-Selke1, Anja Schirmeier1, Julia Gogolok1, Ellen von Hoerschelmann1, Igor M Sauer1, Johann Pratschke1, Marcus Bahra1, Rosa B Schmuck1.   

Abstract

Background and objectives: The Notch signaling pathway plays an important role both in the development of the ductal systems of the pancreas and the bile ducts as well as in cancer development and progression. The aim of this study was to examine the expression of central proteins of the Notch signaling pathway in pancreatobiliary tumors and its influence on patient survival. Materials and
Methods: We compared the receptors (Notch1, Notch4), activating splicing factors (ADAM17), and target genes (HES1) of the Notch pathway and progenitor cell markers with relevance for the Notch signaling pathway (CD44, MSI1) between pancreatic adenocarcinomas (PDAC, n = 14), intrahepatic cholangiocarcinoma (iCC, n = 24), and extrahepatic cholangiocarcinoma (eCC, n = 22) cholangiocarcinomas via immunohistochemistry and ImageJ software-assisted analysis. An Immunohistochemistry (IHC)-score was determined by the percentage and intensity of stained (positive) cells (scale 0-7) and normal and malignant tissue was compared. In the IHC results, patients' (gender, age) and tumor (TNM Classification of Malignant Tumors, Union Internationale contre le Cancer (UICC) stages, grading, and lymphangitic carcinomatosa) characteristics were correlated to patient survival.
Results: For eCC, the expression of CD44 (p = 0.043, IHC-score 3.94 vs. 3.54) and for iCC, the expression of CD44 (p = 0.026, IHC-score 4.04 vs. 3.48) and Notch1 (p < 0.001, IHC-score 2.87 vs. 1.78) was significantly higher in the tumor compared to non-malignant tissue. For PDAC, the expression of ADAM17 (p = 0.008, IHC-score 3.43 vs. 1.73), CD44 (p = 0.012, IHC-score 3.64 vs. 2.27), Notch1 (p = 0.012, IHC-score 2.21 vs. 0.64), and Notch4 (p = 0.008, IHC-score 2.86 vs. 0.91) was significantly higher in the tumor tissue. However, none of the analyzed Notch-signaling related components showed an association to patient survival.
Conclusion: A significant overexpression of almost all studied components of the Notch signaling pathway can be found in the tumor tissue, however, without a significant influence on patient survival. Therefore, further studies are warranted to draw conclusions on Notch pathway's relevance for patient survival.

Entities:  

Keywords:  cancer stem cells; cholangiocarcinoma; notch pathway; pancreatic cancer

Mesh:

Substances:

Year:  2021        PMID: 33498866      PMCID: PMC7911049          DOI: 10.3390/medicina57020105

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  42 in total

1.  Notch4 inhibition reduces migration and invasion and enhances sensitivity to docetaxel by inhibiting Akt/fascin in pancreatic cancer cells.

Authors:  Cui-Juan Qian; Yi-Yi Chen; Xin Zhang; Fu-Qiang Liu; Ting-Ting Yue; Bei Ye; Jun Yao
Journal:  Oncol Lett       Date:  2016-09-07       Impact factor: 2.967

Review 2.  Shaping of the Tumor Microenvironment by Notch Signaling.

Authors:  Olivier Meurette
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma.

Authors:  Jörg Ringel; Ralf Jesnowski; Nicolas Moniaux; Jutta Lüttges; Jens Ringel; Amit Choudhury; Surinder K Batra; Günter Klöppel; Matthias Löhr
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

4.  Autophagy regulates chemoresistance of gastric cancer stem cells via the Notch signaling pathway.

Authors:  L-Q Li; D Pan; S-W Zhang; D -Y-Xie; X-L Zheng; H Chen
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-06       Impact factor: 3.507

5.  Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.

Authors:  Jie Ye; Shun Ming Yuen; Gillian Murphy; Ruiyu Xie; Hang Fai Kwok
Journal:  Eur J Pharm Sci       Date:  2017-05-26       Impact factor: 4.384

Review 6.  Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.

Authors:  Arkadiusz Gzil; Izabela Zarębska; Wiktor Bursiewicz; Paulina Antosik; Dariusz Grzanka; Łukasz Szylberg
Journal:  Mol Biol Rep       Date:  2019-09-05       Impact factor: 2.316

7.  Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.

Authors:  Shuichi Aoki; Masamichi Mizuma; Yayoi Takahashi; Yoichi Haji; Ryo Okada; Tomoya Abe; Hideaki Karasawa; Keiichi Tamai; Takaho Okada; Takanori Morikawa; Hiroki Hayashi; Kei Nakagawa; Fuyuhiko Motoi; Takeshi Naitoh; Yu Katayose; Michiaki Unno
Journal:  BMC Cancer       Date:  2016-11-07       Impact factor: 4.430

8.  Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.

Authors:  Wenchu Wang; Lihui Wang; Atsushi Mizokami; Junlin Shi; Chunlin Zou; Jinlu Dai; Evan T Keller; Yi Lu; Jian Zhang
Journal:  Chin J Cancer       Date:  2017-03-29

9.  ADAM17 inhibition enhances platinum efficiency in ovarian cancer.

Authors:  Nina Hedemann; Christoph Rogmans; Susanne Sebens; Daniela Wesch; Manuel Reichert; Dirk Schmidt-Arras; Hans-Heinrich Oberg; Ulrich Pecks; Marion van Mackelenbergh; Jörg Weimer; Norbert Arnold; Nicolai Maass; Dirk O Bauerschlag
Journal:  Oncotarget       Date:  2018-03-23

Review 10.  Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells.

Authors:  Qingyun Zhu; Yingying Shen; Xiguang Chen; Jun He; Jianghua Liu; Xuyu Zu
Journal:  Onco Targets Ther       Date:  2020-01-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.